Ta'lim innovatsiyasi va integratsiyasi
42-son_1-to’plam_Aprel -2025
ISSN: 3030-3621
167
MANAGEMENT OF PATIENTS WITH UTERINE FIBROIDS IN AN
OUTPATIENT SETTING
Asian International University
Zhumaeva D.R.
Temirova D.O.
Resume.
Strategic approach to treatment of patients with uterine myoma, which
is one of the most frequent causes of hysterectomy. Currently, organ-preserving
treatment of this widespread gynecological nosology is considered a priority. Young
women with uterine myoma who have not fulfilled their reproductive function
currently deserve special attention. On the other hand, in patients approaching
menopause, an important task in achieving it, avoiding a surgical approach, may be
rational, pathogenetically substantiated drug treatment. The implementation of the
effect of progesterone receptor modulators is clinically expressed in a decrease in the
size of myomatous nodes, a marked decrease in blood flow in them, amenorrhea and
relief of anemia.
Key words:
uterine myoma; progesterone receptor modulators; GnRH analogs;
uterine artery embolization; mifepristone.
The social significance of this pathology is difficult to overestimate: myoma is
one of the most common reasons for surgical removal of the uterus. The average age
of detection of uterine myoma is about 35 years, the peak incidence is in the age group
of 35-45 years, however, recently the disease is "getting younger": the incidence of the
disease is growing in the group of young women under 30 years old who have not yet
realized their reproductive function. In combination with the modern trend of late
implementation of reproductive plans, the issue of organ-preserving treatment of MM
is becoming especially relevant [1].
The approach to managing patients with uterine fibroids depends on many
factors and should be guided by modern clinical recommendations, on the one hand,
and be strictly personalized, on the other [1, 2].
Uterine fibroids are defined by:
• sizes of nodes;
• localization;
• age;
• symptoms;
• reproductive plans;
• the patient's well-being;
• the patient's preference for one or another type of treatment.
Ta'lim innovatsiyasi va integratsiyasi
42-son_1-to’plam_Aprel -2025
ISSN: 3030-3621
168
These parameters correspond to modern international principles of management
of patients with uterine fibroids [2, 4]:
• due to the fact that the size, number, location and clinical signs of fibroids in women
vary significantly, treatment should be individualized and, above all, aimed at the range
of clinical manifestations;
• the nature of the symptoms determines the choice of treatment;
• there is no scientific evidence to support the need for surgical treatment of
“asymptomatic” fibroids;
• professional expert communities speak out in support of treatment depending on the
preferences of the individual patient;
• women should be informed of all available treatment options: medication, radiology
and surgery;
• avoid passive tactics leading to hysterectomy.
What does "Individual approach to the treatment of uterine fibroids" mean:
1. Observe.
2. Use medications.
3. Remove the uterus.
4. Remove nodes.
5. Apply regression methods (Uterine artery embolization).
It can be observed only in avascular, clinically insignificant, small, interstitial-
subperitoneal nodes of uterine myoma, mainly in perimenopause. In young patients
with such nodes, much will be determined by the immediate or distant reproductive
plans.
The international professional community has defined the choice of therapy
strategy for small uterine fibroids. The goal of drug treatment is to alleviate or eliminate
symptoms associated with uterine fibroids, and to cause regression of fibroid nodes.
The drug therapy being carried out should be evaluated every 3 months, and if it is
ineffective, other drugs should be prescribed. When choosing a drug therapy option,
not only its effectiveness should be assessed, but also its safety and tolerability [1, 6].
Of the modern drug treatments for fibroids, the most studied (since 2020) is the use of
gonadotropin-releasing hormone agonists (GnRH agonists).
The use of GnRH agonists (according to ATC – gonadotropin-releasing hormone
analogues) is recommended in patients with uterine fibroids and anemia as a
preoperative treatment, as well as to reduce the size of myomatous nodes and reduce
intraoperative blood loss (level of evidence for recommendations A, level of reliability
of evidence – 1). However, GnRH agonist therapy for uterine fibroids is not
recommended for long-term use due to the profile of adverse events and risks
associated with a decrease in estrogen and progesterone levels (requires combination
treatment regimens: GnRH agonists + Add Back).
Ta'lim innovatsiyasi va integratsiyasi
42-son_1-to’plam_Aprel -2025
ISSN: 3030-3621
169
After their cancellation, uterine fibroids resume growing in young women.
Therefore, it is more rational to use GnRH agonists in patients with uterine fibroids
combined with endometrial hyperplasia. And in general: is estrogen ablation necessary
specifically for uterine fibroids? Estrogens in relation to uterine fibroids only stimulate
the expression of progesterone receptors and growth factors, exerting a preparatory
effect. Unlike estrogens, progesterone significantly increases the expression of
epidermal growth factor (EGF) in fibroids, which is its main mitogen, and inhibits
apoptosis [3, 5].
When using progesterone receptor modulators (PRM), their antagonism of the
effect of progesterone on uterine fibroids is exploited [7].
The effect of MPR is realized in several ways: • blocking progesterone receptors;
• suppression of MM growth factors; • inhibition of angiogenesis (reduction in the level
of vascular growth factors (VEGF-A).
It has long been known that three-month courses of treatment with mifepristone
50 mg every other day do not affect the level of liver enzymes [12].
Therefore, at this stage, stabilization of the size of small interstitial-subserous
myomatous nodes, and their possible reduction to clinically insignificant in young
patients with delayed reproductive function can be achieved with the use of
mifepristone [13–15].
Given the presence of a vascularized submucosal-intramural node in
combination with adenomyosis, pronounced clinical symptoms, and the fulfilled
reproductive function, the patient was offered EMM (uterine fibroid embolization) or
drug therapy using a course of Agest as an organ-preserving treatment. The patient
preferred drug therapy. Control ultrasound examination after 3 months. The uterus has
decreased in size to 5–6 weeks, a submucosal-intramural, practically avascular
myomatous node measuring 17×15×13 mm remains along the anterior wall of the
uterus, with a reliable decrease in the submucosal component, smoothing of the cavity
deformation.
The endometrium and ovaries correspond to the MRP procedure. These clinical
examples demonstrate positive dynamics in relation to vascularized myomatous nodes
in women of different age groups, as well as a significant decrease in the echographic
signs of adenomyosis. In our opinion, it was more appropriate to perform EMM for the
patient from the second clinical example, which is fully consistent with: "it is
recommended to perform endovascular embolization of uterine arteries (EMA) in
patients with high surgical risk as an alternative to surgical treatment in the absence of
contraindications in patients who are not planning pregnancy." Moreover, the
optimization of EMM access used by us currently - through the radial artery - reduces
the risk of thrombotic complications (there is no need for tight bandaging of the right
inguinal-femoral region) and eliminates the risk of ascending urinary tract infection
Ta'lim innovatsiyasi va integratsiyasi
42-son_1-to’plam_Aprel -2025
ISSN: 3030-3621
170
(there is no need for a urinary catheter). However, the patient preferred drug treatment,
which at her age could potentially be carried out in intermittent courses [19] up until
menopause.
In conclusion, it can be noted that for uterine fibroid nodes of particularly small
sizes, the drugs of choice are:
• in patients with uterine fibroids who are interested in preserving reproductive function
without surgery and the potential risk of adhesions;
• in patients for whom GnRH agonists are contraindicated (high risk of thrombosis,
osteoporosis, atherosclerosis) or are not appropriate due to age;
• in patients who refuse surgical treatment and who require long-term therapy to
suppress the growth of myomatous nodes;
• in patients planning to undergo organ-preserving surgery to relieve anemia.
Literature
1.
Jumaeva, D. R. (2025). VAGINAL MIKROBIOTSENOZ, BAKTERIAL
VAGINOZ HOLATI VA UNI DAVOLASH USULLARI.
Modern education and
development
,
19
(3), 65-77.
2.
Djumaeva,
D.
R.
(2025).
TOMOSINTEZ
BILAN
RAQAMLI
MAMMOGRAFIYA
NAZORATI
OSTIDA
KO'KRAK
BEZINING
STEREOTAKSIK BIOPSIYASI.
Modern education and development
,
19
(3), 53-
64.
3.
Жумаева, Д. Р. (2025). ОПТИМИЗАЦИЯ МЕТОДОВ ДИАГНОСТИКИ
РАЗЛИЧНЫХ
ФОРМ
ЭНДОМЕТРИОЗА
У
ЖЕНЩИН
РЕПРОДУКТИВНОГО ВОЗРАСТА.
Modern education and development
,
19
(3),
78-87.
4.
Жумаева, Д. Р. (2025). СОСТОЯНИЕ МИКРОБИОЦЕНОЗА ВЛАГАЛИЩА,
БАКТЕРИАЛЬНЫЙ ВАГИНОЗ И ВОЗМОЖНОСТИ ЕГО ЛЕЧЕНИЯ.
Modern
education and development
,
19
(3), 88-101.
5.
Жумаева, Д. Р. (2025). АНАЛИЗ ГИНЕКОЛОГИЧЕСКОЙ ПАТОЛОГИИ У
ЖЕНЩИН
ПОЗДНЕГО
РЕПРОДУКТИВНОГО
ПЕРИОДА
ЗАБОЛЕВАНИЯМИ МОЛОЧНОЙ ЖЕЛЕЗЫ.
Modern
education
and
development
,
19
(3), 102-112.
6.
DR Zhumaeva, D. R. (2024). The State of the Vaginal Microbiocenosis, Bacterial
Vaginosis andits Treatment Options.
American Journal of Bioscience and Clinical
Integrity
,
1
(11), 78-83.
7.
Хикматова, Н. И., & Жумаева, Д. Р. (2023). Инвазивные И Неинвазивные
Методы Диагностики Заболевания Молочных Желез.
Central Asian Journal of
Medical and Natural Science
,
4
(6), 652-658.
8.
ZHUMAEVA, D. (2024). OPTIMIZATION OF METHODS OF DIAGNOSTICS
OF
VARIOUS
FORMS
OF
ENDOMETRIOSIS
IN
WOMEN
OF
REPRODUCTIVE
AGE.
Valeology:
International
Journal
of
Medical
Anthropology and Bioethics (2995-4924)
,
2
(9), 120-125.
Ta'lim innovatsiyasi va integratsiyasi
42-son_1-to’plam_Aprel -2025
ISSN: 3030-3621
171
9.
Абдукаримов, У. Г., Ихтиярова, Г. А., & Джумаева, Д. Р. (2024). Скрининг
Рака Молочной Железы: Настоящее И Будущее. Обзор Литературы.
Research
Journal of Trauma and Disability Studies
,
3
(2), 144-148.
10.
Zhumaeva, D. R. (2025). IMMUNOLOGICAL CHARACTERISTICS OF THE
ENDOMETRIUM IN WOMEN WITH IMPAIRED FERTILITY.
Modern
education and development
,
19
(2), 390-402.
11.
Jumaeva, D. R. (2025). REPRODUKTIV BUZISHLI AYOLLARDA
ENDOMETRIYNING IMMUNOLOGIK XUSUSIYATLARI.
Modern education
and development
,
19
(2), 403-415.
12.
Jumaeva, D. R. (2025). REPRODUKTIV BUZISHLI AYOLLARDA
SURUNKALI AUTOIMMUN ENDOMETRITNNING KECHISHI.
Modern
education and development
,
19
(2), 375-389.
13.
Jumaeva, D. R., & Temirova, D. O. (2025). ETIOLOGY AND DIAGNOSTIC
CRITERIA OF CERVICAL EROSION.
TADQIQOTLAR
,
58
(3), 126-134.
14.
Jumaeva, D. R., & Temirova, D. O. (2025). BACHADON BO'YNI
EROZIYASINING
ETIOLOGIYASI
VA
DIAGNOSTIK
MEZONLARI.
TADQIQOTLAR
,
58
(3), 117-125.
15.
Jumaeva, D. R., & Temirova, D. O. (2025). MODERN POSSIBILITIES OF
TREATMENT OF MASTALGIA AGAINST THE BACKGROUND OF
MASTOPATHY.
TADQIQOTLAR
,
58
(3), 144-151.
16.
Джумаева, Д. Р., & Темирова, Д. О. (2025). СОВРЕМЕННЫЕ
ВОЗМОЖНОСТИ
ЛЕЧЕНИЯ
МАСТАЛГИИ
НА
ФОНЕ
МАСТОПАТИИ.
TADQIQOTLAR
,
58
(3), 135-143.
17.
Темирова, Д. О., & Жумаева, Д. Р. (2025). ИНФЕКЦИЯ МОЧЕВЫХ ПУТЕЙ
У БЕРЕМЕННЫХ.
TADQIQOTLAR
,
58
(3), 96-105.
18.
Темирова, Д. О., & Жумаева, Д. Р. (2025). ВНУТРИПЕЧЕНОЧНЫЙ
ХОЛЕСТАЗ ПРИ БЕРЕМЕННОСТИ.
TADQIQOTLAR
,
58
(3), 106-116.
19.
Темирова, Д. О., & Жумаева, Д. Р. (2025). ПРЕЭКЛАМПСИЯ–ПАТОЛОГИЯ,
ПРИВОДЯЩАЯ
К
ОСЛОЖНЕНИЯМ
ДЛЯ
МАТЕРИ
И
ПЛОДА.
TADQIQOTLAR
,
58
(3), 85-95.
20.
Jumayeva, D. R. (2025). ACUTE RESPIRATORY INFECTIONS INSTIGATORS
CHARACTERISTIC AND THEIR CLINICAL IMPORTANCE.
Modern Science
and Research
,
4
(3), 734-742.
21.
Zhumaeva, D. R. (2025). MASTODYNYA: POSSIBILITIES OF THERAPY
USING MICRONIZED PROGESTERONE.
Modern Science and Research
,
4
(2),
912-919.
22.
Temirova, D. O. (2024). Diagnosis of Cervical Erosion.
American Journal of
Bioscience and Clinical Integrity
,
1
(11), 84-89.
23.
Темирова, Д. А. (2024). СОВРЕМЕННЫЕ МЕТОДЫ ЛЕЧЕНИЯ СИНДРОМА
АШЕРМАНА.
Modern education and development
,
16
(10), 132-142.
24.
Темирова, Д. О. (2024). КЛИНИЧЕСКОЕ ЗНАЧЕНИЕ МИОМЫ МАТКИ В
ГИНЕКОЛОГИИ.
Modern education and development
,
16
(10), 116-131.
25.
Olimjonovna, T. D. (2024). THE SYNDROME OF UNFORTUNATE
CONSEQUENCES HELPPA.
Modern education and development
,
16
(10), 156-
166.
Ta'lim innovatsiyasi va integratsiyasi
42-son_1-to’plam_Aprel -2025
ISSN: 3030-3621
172
26.
Olimjonovna, T. D. (2024). UTERINE PROLAPSE IS A DELICATE PROBLEM
FOR WOMEN.
Modern education and development
,
16
(10), 167-176.
27.
Olimjonovna, T. D. (2024). BACTERIAL VAGINOSIS IS A DANGEROUS
DISEASE.
Modern education and development
,
16
(10), 143-155.
28.
Temirova,
D.
(2024).
ADENOMYOSIS
AND
DISORDERS
OF
REPRODUCTIVE FUNCTION.
European Journal of Modern Medicine and
Practice
,
4
(10), 195-199.
29.
Темирова, Д. О., & Мухитдинова, Х. С. (2025). РАЗРЫВ МАТКИ–
СЕРЬЕЗНОЕ ОСЛОЖНЕНИЕ В АКУШЕРСТВЕ.
Modern education and
development
,
19
(2), 365-374.
30.
Мухитдинова, Х. С., & Темирова, Д. О. (2025). КЛИНИЧЕСКОЕ ФАКТОРЫ
СТРОЕНИЕ СПЕРМАТОЗОИДОВ ПРИ МУЖСКОГО БЕСПЛОДИЯ.
Modern
education and development
,
19
(2), 416-426.
31.
Мухитдинова, Х. С., & Темирова, Д. О. (2025). ОСОБЕННОСТИ
ПАТОЛОГИЯ ЯИЧНИКОВ В СТРУКТУРЕ ГИНЕКОЛОГИЧЕСКОЙ
ЗАБОЛЕВАЕМОСТИ.
Modern education and development
,
19
(2), 450-463.
32.
Темирова, Д. О., & Мухитдинова, Х. С. (2025). ВНЕМАТОЧНАЯ
БЕРЕМЕННОСТЬ–ЗАБОЛЕВАНИЕ,
ТРЕБУЮЩЕЕ
НЕОТЛОЖНОЙ
ПОМОЩИ.
Modern education and development
,
19
(2), 342-354.
33.
Темирова,
Д.
О.,
&
Мухитдинова,
Х.
С.
(2025).
МОРФОФУНКЦИОНАЛЬНЫЕ
ОСОБЕННОСТИ
ТРИХОМОНИАЗА.
Modern education and development
,
19
(2), 355-364.
34.
Темирова, Д. О., & Мухитдинова, Х. С. (2025). ПРЕЖДЕВРЕМЕННАЯ
ОТСЛОЙКА ПЛАЦЕНТЫ.
Modern education and development
,
19
(2), 316-327.
35.
Темирова, Д. О., & Мухитдинова, Х. С. (2025). СПКЯ-ОДНА ИЗ ПРИЧИН
БЕСПЛОДИЯ.
Modern education and development
,
19
(2), 328-341.
36.
Temirova, D. O. (2025). THE ROLE OF ENDOMETRIOSIS IN THE FEMALE
REPRODUCTIVE SYSTEM.
TADQIQOTLAR
,
58
(3), 55-65.
37.
Темирова, Д. (2025). АКТУАЛЬНОСТЬ АНОМАЛЬНОГО МАТОЧНОГО
КРОВОТЕЧЕНИЯ.
Modern Science and Research
,
4
(3), 759-768.
38.
Temirova, D. (2025). ECTOPIC PREGNANCY IS A DISEASE REQUIRING
EMERGENCY ASSISTANCE.
Modern Science and Research
,
4
(2), 920-928.
39.
Saloxiddinovna, X. Y. (2024). MORPHOFUNCTIONAL FEATURES OF THE
STRUCTURE AND DEVELOPMENT OF THE OVARIES.
EUROPEAN
JOURNAL OF MODERN MEDICINE AND PRACTICE
,
4
(4), 220-227.
40.
Saloxiddinovna, X. Y. (2024). Modern Views on the Effects of the Use of
Cholecalciferol on the General Condition of the Bod.
JOURNAL OF
HEALTHCARE AND LIFE-SCIENCE RESEARCH
,
3
(5), 79-85.
41.
Халимова, Ю. С., & Хафизова, М. Н. (2024). МОРФО-ФУНКЦИОНАЛЬНЫЕ
И КЛИНИЧЕСКИЕ АСПЕКТЫ СТРОЕНИЯ И РАЗВИТИЯ ЯИЧНИКОВ
(ОБЗОР ЛИТЕРАТУРЫ).
TADQIQOTLAR. UZ
,
40
(5), 188-198.
42.
Халимова, Ю. С. (2024). Морфологические Особенности Поражения Печени
У Пациентов С Синдромом Мэллори-Вейса.
Journal of Science in Medicine and
Life
,
2
(6), 166-172.
Ta'lim innovatsiyasi va integratsiyasi
42-son_1-to’plam_Aprel -2025
ISSN: 3030-3621
173
43.
Xalimova, Y. S. (2024). Morphology of the Testes in the Detection of
Infertility.
Journal of Science in Medicine and Life
,
2
(6), 83-88.
44.
KHALIMOVA, Y. S. (2024). MORPHOFUNCTIONAL CHARACTERISTICS
OF TESTICULAR AND OVARIAN TISSUES OF ANIMALS IN THE AGE
ASPECT.
Valeology: International Journal of Medical Anthropology and
Bioethics
,
2
(9), 100-105.
45.
Salokhiddinovna, K. Y. (2024). IMMUNOLOGICAL CRITERIA OF
REPRODUCTION AND VIABILITY OF FEMALE RAT OFFSPRING UNDER
THE INFLUENCE OF ETHANOL.
EUROPEAN JOURNAL OF MODERN
MEDICINE AND PRACTICE
,
4
(10), 200-205.
46.
Salokhiddinovna, K. Y., Saifiloevich, S. B., Barnoevich, K. I., & Hikmatov, A. S.
(2024). THE INCIDENCE OF AIDS, THE DEFINITION AND CAUSES OF THE
DISEASE.
ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В
МИРЕ
,
55
(2), 195-205.
47.
Nematilloevna, K. M., & Salokhiddinovna, K. Y. (2024). IMPORTANT
FEATURES IN THE FORMATION OF DEGREE OF COMPARISON OF
ADJECTIVES IN LATIN.
ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ
ИДЕИ В МИРЕ
,
55
(2), 150-157.
48.
Saloxiddinovna, X. Y., & Ne’matillaevna, X. M. (2024). FEATURES OF THE
STRUCTURE OF THE REPRODUCTIVE ORGANS OF THE FEMALE
BODY.
ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В
МИРЕ
,
55
(2), 179-183.
49.
Хафизова, М. Н., & Халимова, Ю. С. (2024). ИСПОЛЬЗОВАНИЕ
ЧАСТОТНЫХ ОТРЕЗКОВ В НАИМЕНОВАНИЯХ ЛЕКАРСТВЕННЫХ
ПРЕПАРАТОВ
В
ФАРМАЦЕВТИКЕ.
ОБРАЗОВАНИЕ
НАУКА
И
ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ
,
55
(2), 172-178.
50.
Хафизова, М. Н., & Халимова, Ю. С. (2024). МОТИВАЦИОННЫЕ МЕТОДЫ
ПРИ
ОБУЧЕНИИ
ЛАТЫНИ
И
МЕДИЦИНСКОЙ
ТЕРМИНОЛОГИИ.
ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ
В МИРЕ
,
55
(2), 165-171.
51.
Халимова, Ю. С., & Хафизова, М. Н. (2024). ОСОБЕННОСТИ СОЗРЕВАНИЕ
И ФУНКЦИОНИРОВАНИЕ ЯИЧНИКОВ.
ОБРАЗОВАНИЕ НАУКА И
ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ
,
55
(2), 188-194.
52.
Халимова, Ю. С., & Хафизова, М. Н. (2024). КЛИНИЧЕСКИЕ АСПЕКТЫ
ЛИЦ
ЗЛОУПОТРЕБЛЯЮЩЕЕСЯ
ЭНЕРГЕТИЧЕСКИМИ
НАПИТКАМИ.
TADQIQOTLAR. UZ
,
40
(5), 199-207.
53.
Халимова, Ю. С., & Хафизова, М. Н. (2024). кафедра Клинических наук
Азиатский международный университет Бухара, Узбекистан.
Modern
education and development
,
10
(1), 60-75.
54.
Халимова, Ю. С., & Хафизова, М. Н. (2024). КЛИНИЧЕСКИЕ
ОСОБЕННОСТИ ЗАБОЛЕВАНИЙ ВНУТРЕННИХ ОРГАНОВ У ЛИЦ,
СТРАДАЮЩИХ АЛКОГОЛЬНОЙ ЗАВИСИМОСТЬЮ.
TADQIQOTLAR.
UZ
,
40
(5), 240-250.
Ta'lim innovatsiyasi va integratsiyasi
42-son_1-to’plam_Aprel -2025
ISSN: 3030-3621
174
55.
Халимова, Ю. С., & Хафизова, М. Н. (2024). МОРФО-ФУНКЦИОНАЛЬНЫЕ
И
КЛИНИЧЕСКИЕ
АСПЕКТЫ
ФОРМИРОВАНИЯ
КОЖНЫХ
ПОКРОВОВ.
Modern education and development
,
10
(1), 76-90.
56.
Khalimova, Y. S. (2024). Features of Sperm Development: Spermatogenesis and
Fertilization.
American Journal of Bioscience and Clinical Integrity
,
1
(11), 90-98.
57.
Salokhiddinovna, K. Y., & Nematilloevna, K. M. (2024). MODERN
MORPHOLOGY OF HEMATOPOIETIC ORGANS.
Modern education and
development
,
16
(9), 50-60.
58.
Khalimova, Y. (2025). MORPHOLOGY OF PATHOLOGICAL FORMS OF
PLATELETS.
Modern Science and Research
,
4
(2), 749-759.
59.
Salokhiddinovna, K. Y., & Nematilloevna, K. M. (2025). MODERN
MORPHOLOGY OF HEMATOPOIETIC ORGANS.
Modern education and
development
,
19
(2), 498-508.
60.
Халимова, Ю. С., & Хафизова, М. Н. (2025). СОВРЕМЕННАЯ
МОРФОЛОГИЯ КРОВЕТВОРНЫХ ОРГАНОВ.
Modern education and
development
,
19
(2), 487-497.
61.
Халимова, Ю. С., & Хафизова, М. Н. (2025). ГИСТОЛОГИЧЕСКАЯ
СТРУКТУРНАЯ МОРФОЛОГИЯ НЕФРОНОВ.
Modern education and
development
,
19
(2), 464-475.
62.
Saloxiddinovna, X. Y., & Nematilloevna, X. M. (2025). NEFRONLARNING
GISTOLOGIK
TUZILISH
MORFOLOGIYASI.
Modern
education
and
development
,
19
(2), 509-520.
63.
Saloxiddinovna, X. Y., & Ne’matilloyevna, X. M. (2025). QON YARATUVCHI
A'ZOLARNING ZAMONAVIY MORFOLOGIYASI.
Modern education and
development
,
19
(2), 476-486.
64.
Xalimova, Y. (2025). MODERN CONCEPTS OF BIOCHEMISTRY OF BLOOD
COAGULATION.
Modern Science and Research
,
4
(3), 769-777.
